TRPM8 antagonism is deeply related to analgesic in vivo effects and has been proposed as a suitable pharmacological strategy for the treatment of chronic pain, migraine, and painful syndromes [39,40,41]. The gene discussed is TRPM8; the disease is migraine disorder.